In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on…

Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive…

Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical…

In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls…

Blue-chip drug makers holding USD 200 billion in cash, mostly overseas, will start investing more of it in mergers and acquisitions (M&A) after…

While pledging to lower drug prices has proved popular, the Trump administration’s proposed FDA reform has been getting some pharmaceutical…

Take our poll on Donald Trump and Pharma at the bottom of the article Speaking at a White House meeting with senior pharmaceutical executives, US…